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ABSTRACT
TIA-1 related protein binds avidly to uridine-rich ele-
ments in mRNA and pre-mRNAs of a wide range of
genes, including interleukin (IL)-8 and vascular
endothelial growth factor (VEGF). The protein has
diverse regulatory roles, which in part depend on
the locus of binding within the transcript, including
translationalcontrol,splicingandapoptosis.Here,we
observedselectiveandpotentinhibitionofTIAR–RNP
complex formation with IL-8 and VEGF 30-untrans-
lated regions (30-UTRs) using thymidine-rich deoxy-
oligonucleotide (ODN) sequences derived from the
VEFG 30-UTR. We show by ultraviolet crosslinking
and electrophoretic mobility shift assays that TIAR
can bind directly to single-stranded, thymidine-rich
ODNs but not to double-stranded ODNs containing
the same sequence. TIAR had a nearly 6-fold greater
affinity for DNA than RNA (Kdapp ¼ 1:6 3 10
 9 M
versus 9:4 3 10
 9M). Truncation of TIAR indicated
that the high affinity DNA-binding site overlaps with
theRNA-bindingsiteinvolvingRNArecognitionmotif
2 (RRM2). However, RRM1 alone could also bind to
DNA. Finally, we show that TIAR can be displaced
from single-stranded DNA by active transcription
through the binding site. These results provide a
potential mechanism by which TIAR can shuttle
between RNA and DNA ligands.
INTRODUCTION
TIA-1 related protein (TIAR) is a high-afﬁnity RNA-binding
protein that promotes apoptosis (1–3). It possesses three RNA
recognition motifs (RRMs) and shares 80% amino acid
homology with TIA-1 (3). Both proteins have a predilection
for binding uridylate (U)-rich sequences (4). Two relevant
binding targets for TIAR and TIA-1 have been identiﬁed: the
30-untranslated regions (30-UTRs)ofcertain mRNAsincluding
interleukin (IL)-8, human matrix metalloproteinase (MMP)-
13, cyclooxygenase-2, and tumor necrosis factor (TNF)-a, and
the U-rich sequence near 50 splice sites of several pre-mRNAs,
such as ﬁbroblast growth receptor 2, Fas, human calcitonin/
CGRP and TIAR itself (5–11). When binding to the 30-UTR,
such as with TNF-a or MMP-13, these proteins have been
linked to translational silencing possibly by sequestering the
mRNA away from the translational machinery to cytoplasmic
stress granules (7,9,10,12–15). By binding to pre-mRNAs, on
the other hand, TIAR and TIA-1 modulate splicing
(5,8,12,16,17). In certain cell systems, TIA-1 may promote
apoptosis by producing the alternatively spliced, membrane-
bound isoform of Fas responsible for relaying the apoptotic
signal (5). While RRM2 of TIAR and TIA-1 is essential for
binding to U-rich sequences, little is known about the binding
targets of RRM1 and RRM3. Here, we demonstrate that TIAR
and TIA-1 can both bind thymidine-rich single-stranded DNA
(ssDNA). A more in-depth analysis of TIAR indicates that it
binds DNA targets with a higher afﬁnity than RNA and, for the
ﬁrst time, that RRM1 can bind to these DNA targets. Using an
in vitro model of transcription, we show that TIAR can be
displaced from DNA by active transcription through the DNA-
binding site. This ﬁnding provides a potential mechanism by
which TIAR can shuttle between DNA and RNA ligands.
MATERIALS AND METHODS
Probes and constructs
All deoxyoligonucleotides (ODNs) were purchased from
Sigma–Genosys (The Woodlands, TX) and the rVEGF-
AS1 ribonucleotide from Integrated DNA Technologies
(Coralville, IA). Sequences of ODNs and the RNA oligonu-
cleotide are shown in the Table 1. Radiolabeled and biotiny-
lated IL-8 and vascular endothelial growth factor (VEGF)
30-UTR riboprobes were synthesized and quantiﬁed as
described previously (11,18,19). All oligonucleotide probes
were labeled with [g-
32P]ATP (Amersham, Piscataway, NJ)
using T4 polynucleotide kinase according to the manufac-
turer’s speciﬁcations (Promega, Madison, WI). Probes were
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doi:10.1093/nar/gki763puriﬁed using Quick Spin Oligo Columns (Roche, Indianapo-
lis, IN). Plasmids containing TIAR-b (short) and TIA-1
cDNAs were generously provided by Dr Paul Anderson (4).
For TIAR protein expression, the cDNA was subcloned into a
pET21a vector containing a His tag at the C-terminus. Trun-
cated TIAR constructs were generated by PCR and subcloned
into the Nhe1 and Xho1 sites of pET21a using a common
downstream primer (50-GTTTACACTCGAGCTGTGTTT-
GGTAACTTGCCAT-30) and the following upstream primers:
RRM 2,3 (50-CATAGCGGCTAGC TCCAATCACTTCCAT-
GTGT-30), and RRM 3 (50-CATAGCGGCTAGC GATGTA-
GTAAACCAGTCAA-30). The RRM1 construct was cloned
into the BamH1 and Xho1 sites of pET21b using the following
primers: upstream, 50-AGATACAAGGATCCAATGGAAG-
ACGACGGGCAG-30 and downstream, 50-GTTTACACTC-
GAGAGTATCTTTTTTCTGGCTA-30. All constructs were
veriﬁed by sequence and restriction analysis. Protein biosyn-
thesis and puriﬁcation were performed as described previously
(20). All proteins were dialyzed and stored in 0.15 M KCl,
40 mM Tris, pH 7.5, 1 mM EDTA and 1 mM MgCl2. HuR and
TIA-1were expressed andpuriﬁedasglutathione S-transferase
(GST) fusion proteins as described previously (4,19). To
ensure accurate quantiﬁcation of His-tagged proteins, we uti-
lized an enzyme-linked immunosorbent assay (ELISA) with
two standard controls. The ﬁrst standard was full-length TIAR
and the second was an unrelated His-tagged protein, Eg5.
Brieﬂy, the standard and test proteins were diluted serially
and incubated in an ELISA plate. The following day, the
plate was washed, blocked and incubated with the Penta-
His antibody (0.2 mg/ml) according to the manufacturer’s
speciﬁcations (Qiagen, Valencia, CA). On the next day, the
plate was washed and incubated with an anti-mouse alkaline
phosphatase-conjugated IgG (Pierce Endogen, Rockford, IL)
and developed with p-nitrophenyl phosphate (Sigma–Aldrich,
St Louis, MO). The OD (at 405 nm) was measured and plotted
to determine the linear range of the standards. The mutant
proteins were tested at three different dilutions and the con-
centration was extrapolated based on the dilution that fell
withinthe linear range. Theestimated concentrationcorrelated
with both standard proteins.
RNA-binding assays
All ultraviolet (UV) crosslinking reactions were carried out as
previously described (21). For afﬁnity binding assays, varying
concentrations of recombinant protein (all in excess of probe)
were mixed with labeled probe and UV crosslinked. The
electrophoresed band was quantiﬁed on a phosphorimager.
A non-linear regression curve and a Kdapp were calculated
using GraphPad Prism software v. 4.02 (GraphPad Software,
San Diego, CA). For immunoprecipitation, 2 ml of an anti-
TIAR antibody to the C-terminus (Santa Cruz Biotechnology,
Inc. Santa Cruz, CA) were added after UV crosslinking in the
presence of 1000 ml of immunoprecipitation (IP) buffer as
described previously (21). The ELISA-based RNA-binding
assay was carried out as described previously (22). The
RNA-binding reactions for electrophoretic mobility shift
assays (EMSAs) were carried out identically to the UV-
crosslinking reaction. After the ﬁnal 10 min incubation at
room temperature, loading buffer was added (0.5· TBE,
10% glycerol, 0.25% bromophenol blue and 0.25% xylene
cyanol) and the samples were electrophoresed in a native
6% polyacrylamide gel at 4 C based on a published pro-
tocol (23). For the supershift assay, the anti-TIAR antibody
(or IgG control) was added after the binding reaction and
allowed to incubate at room temperature for 30 min before
electrophoresis.
Competition assays
With all competition assays, unlabeled competitor was added
simultaneously with the probe prior to adding TIAR protein
or cell extract. For double-stranded ODN competitions, the
unlabeled complementary (or control) ODN was mixed with
labeled probe in annealing buffer (10 mM Tris, pH 8.0, 50 mM
NaCl and 1 mM EDTA), boiled and allowed to cool  1 h. The
duplexed ODN was then usedinthe bindingassay.Forbinding
assaysinvolvingpre-UV crosslinkedprotein,TIAR wasmixed
with 5-fold excess unlabeled ODN or RNA oligonucleotide in
binding buffer and then UV crosslinked. An aliquot of this
mixture was then used in a subsequent binding reaction with
labeled probe.
RNA transcription assay
The following ODNs were synthesized and polyacrylamide-
gel puriﬁed (Sigma–Genosys, The Woodlands, TX): T7tiar,
50-AAGATGAGAATAGTATTTTTTTTTTTTCGTATTGG-
AACAATATAAACAATACTATCCCTATAGTGAGTCG-
TATTA-30 and T7, 50-TAATACGACTCACTATAGGG-30.
The ODNs were annealed as described above to form a duplex
ODN in the T7 recognition sequence. The partially duplexed
ODN was used as a template (1.3 pmol) in a T7 transcription
reaction using a kit (Ambion, Austin, TX) and [
32P]UTP with
or without rCTP. Transcripts were electrophoresed on a 8 M
urea/6% polyacrylamide gel and exposed to a phosphorim-
ager. For TIAR binding and displacement experiments, the
T7tiar ODN was labeled with [g-
32P]ATP as described
above and then annealed to the T7 ODN. TIAR was incubated
with the partially duplexed ODN in RNA-binding buffer for
20min atroom temperature and then added to the transcription
mixture using unlabeled UTP with or without rCTP. T7 RNA
polymerase was added and the reaction was carried out at
room temperature for various time intervals, followed by
Table 1. Summary of the oligonucleotide sequences used in the analysis of
TIAR binding binding properties
Oligonucleotide Sequence
C+ ATTAGATTCCCCCCCCCCCCCCCC
GC+ CACGCGGCCCCGCCTGGGCGC
Oligo(dT) TTTTTTTTTTTTTTT
IL8-AS1 TTAATATCTAAAATAAAATAAATT
VEGF-AS1 AGAATTAAATTCTTTAATACAAAATGCTTTTTTTT-
TTTTA
VEGF-AS1a AGAATTAAATTCTTTAATAC
VEGF-AS1b AAAATGCTTTTTTTTTTTTA
VEGF-AS1b.1 AAAATGCTTTTTTTTTTA
VEGF-AS1b.2 AAAATGCTTTTTTT
VEGF-AS1b.3 TTTTTTTTTA
rVEGF-AS1 AAAAUGCUUUUUUUUUUUUA
VEGF-AS2 AATAAATAAATGATAACAAATATTAAAATTAAA-
AAAG
VEGF-AS3 AATATCTTTTCCCCACAATTATTACGGATAAAC
VEGF-AS4 TAAAAATAAATATGTACTACGGAATATCTCGAAA-
AAC
VEGF-S2 CTTTTTTAATTTTAATATTTGTTATCATTTATTTATT
4508 Nucleic Acids Research, 2005, Vol. 33, No. 14UV crosslinking and immunoprecipitation with the anti-TIAR
antibody as described above. All reactions were then elec-
trophoresed on a SDS–acrylamide gel.
Cell culture and extract preparation
HS578t cells were purchased from the ATCC (Rockville, MD)
and maintained in standard DMEM supplemented with 10%
fetal bovine serum, 4 mM glutamine and 0.01 mg/ml bovine
insulin in a humidiﬁed atmosphere with 10% CO2. Cells were
grown to 75–90% conﬂuency and then washed and scraped in
phosphate-buffered saline (PBS) and pelleted. Nuclear
extracts were prepared from cell pellets in the presence of
protease inhibitors using the NE-PER Nuclear and Cytoplas-
mic Extraction Reagents (Pierce, Rockford, IL) according to
the manufacturer’s protocol.
RESULTS
VEGF antisense ODNs block TIAR binding to
IL-8 and VEGF 30-UTR
We initially constructed antisense (AS) ODNs complementary
to the AU-rich elements (ARE) in the IL-8 and VEGF 30-UTRs
(Table 1) to disrupt RNP complexes by duplexing with the
mRNA. We incubated the probe/ODN mixture with nuclear
extract from HS578t breast cancer cells, followed by UV
crosslinking and electrophoresis. We observed that one of
the VEGF-speciﬁc ODNs (VEGF-AS1) effectively inhibited
the formation of RNP complexes in the 42–45 kDa size
range, with both the IL-8 and VEGF 30-UTR RNA probes
(Figure 1A). We had previously identiﬁed TIAR as the
RNA-binding protein in these complexes (11). A near total
loss of binding was observed at very low concentrations
of ODN (5-fold excess), indicating a potent inhibition. Two
control ODNs, VEGF-AS2 and IL-8-AS1, did not prevent the
formation of these complexes, even up to 100-fold excess of
probe (data not shown). The other RNP complexes, which
include HuR and KSRP as identiﬁed, were not competed by
VEGF-AS1. To conﬁrm that this RNP complex included
TIAR, we carried out the UV-crosslinking competition
assay with the IL-8 30-UTR probe and then immunoprecipi-
tated the extract with a TIAR-speciﬁc antibody. As shown in
Figure 1B, RNP complexes in the 42–45 kDa size range were
immunoprecipitated with the anti-TIAR antibody (lanes 1 and
2), and the complex formation was blocked in the presence of
VEGF AS1 but not AS2 ODNs. The loss of RNP complex,
once again, occurred at low concentrations of ODN. We next
conﬁrmed this inhibitory effect using an ELISA-based RNA-
binding assay previously described for ELAV proteins (22).
This assay does not utilize UV crosslinking. Recombinant
TIAR (b isoform) (3) and HuR proteins were adsorbed to
the ELISA well and incubated with a biotinylated IL-8
30-UTR probe. Potent inhibition of RNA binding was observed
with TIAR but not HuR (Figure 1C), in a range of ODN
Figure1.TIARbindingtoVEGForIL-830-UTRRNAiscompetedbyaT-richantisenseODN(VEGF-AS1)derivedfromtheVEGF30-UTR.(A)UVcrosslinkingof
HS578t nuclear extract with IL-8 or VEGF 30-UTR RNA probes in the presence of varying concentrations of competitor ODNs. (B) Immunoprecipitation of UV-
crosslinked extracts with an anti-TIAR antibody after binding competition with ODNs and the IL-8 30-UTR RNA probe. (C) ELISA RNA-binding assay
with recombinant HuR or TIAR and a biotinylated IL-8 30-UTR probe in the presence of VEGF-AS1 competitor ODN. Molecular markers (kDa) are shown to
the left of the blots.
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(2- to 10-fold excess).
TIAR binds directly to thymidine-rich ssDNA
The lack of sequence homology between VEGF-AS1 and the
IL-8 30-UTR suggested that the binding inhibition was not
due to duplexing between the DNA and RNA strands. We
next tested the possibility that the inhibition was due to direct
binding of the ODN to TIAR. We radiolabeled VEGF-AS1
and AS2 ODNs and performed an UV-crosslinking assay
with recombinant TIAR (Figure 2). With TIAR, we observed
a strong crosslinked band with VEGF-AS1 but not with
VEGF-AS2 ODN (Figure 2A, upper panel). The IL-8
30-UTR riboprobe was used as a control. We performed the
same assay with recombinant HuR and observed binding only
with the IL-8 30-UTR riboprobe (lower panel). The concen-
tration of HuR was  6-fold greater than that used for TIAR
(127 nM versus 22 nM) and  40-fold greater than the Kd
reported for RNA binding (24). To delineate sequences impor-
tant for binding, we divided the VEGF-AS1 ODN into 50 and
30 fragments of equal length (VEGF-AS1a and VEGF-AS1b,
see Table 1). We observed a strong band with VEGF-AS1b
versus a weak one with VEGF-AS1a. The most striking
sequence difference between the two ODNs was the presence
of a 12 nt stretch of thymidines in VEGF-AS1b. We deter-
mined whether this sequence pattern alone was sufﬁcient for
binding, or whether binding was dependent on secondary
structure (e.g. with the adenines at the 50 end of the VEGF-
AS1b). We tested oligo(dT), an iteration of 15 thymidines, and
found strong binding, supporting the former possibility. The
modest binding observed with VEGF-AS1a (containing three
consecutive thymidines) suggested that binding efﬁciency
depends on the length of the thymidine stretch. ODNs that
had one or two consecutive thymidines showed no binding
(VEGF-AS2, AS4andIL-8 AS1),whilethosewithstretchesof
three to four thymidines showed modest binding (VEGF-AS1a
and VEGF-AS3). In no instance was there any binding
observed with HuR other than the control RNA probe.
Using the same crosslinking assay, we found that the closely
related TIA-1 protein (fused to GST) could also bind VEGF-
AS1 and the RNA homolog, rVEGF-AS1, but not VEGF-AS2
(Figure 2B). As an alternative analysis of DNA binding, we
performed EMSA with the VEGF-AS1b ODN and found a
prominent shifted complex (Figure 2C). At higher concentra-
tions of TIAR, a second shifted complex was observed con-
sistent with homodimerization of the protein. No complexes
were observed with the negative control ODN (VEGF-AS2),
Figure 2. TIAR binds directly to ODNs. (A) UV-crosslinking results with recombinant TIAR (22 nM) or HuR (127 nM) and radiolabeled oligonucleotides as
indicated.AradiolabeledIL-830-UTRriboprobewasusedasacontrolforbothproteins.(B)UVcrosslinkingofrecombinantGST-TIA-1witholigonucleotideprobes
as indicated. (C) Results of EMSA with recombinant TIAR and oligonucleotide probes as indicated. The range of TIAR concentrations was from 35–210 nM.
Shiftcomplexesareindicatedbyarrows.(D)EMSAofrecombinantTIARandVEGF-AS1bprobewiththeadditionofincreasingamountsofunlabeledVEGF-AS1b
(1·–100·). The addition of an anti-TIAR antibody (T), but not control IgG (C) obliterated the shifted complexes with VEGF-AS1b and produced a supershifted
complex (indicated by an arrow in the right panel).
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beled VEGF-AS1b (Figure 2D). Addition of the anti-TIAR
antibody, but not control IgG, obliterated the shifted complex
and also produced a supershifted complex.
We next analyzed more precisely the sequence require-
ments for optimal inhibition of RNA binding to TIAR. In
this assay, a competitor ODN was added to the reaction
simultaneously with the IL-8 30-UTR riboprobe prior to UV
crosslinking. The resultant band was quantitated and com-
pared with the control reaction with no competitor added.
Consistent with the binding data shown in Figure 2, there was
potent inhibition with VEGF-AS1 but not with VEGF-AS2
(Figure 3A, upper panel). Interestingly, VEGF-S2, the reverse
complement of the negative control ODN VEGF-AS2, con-
tains stretches of thymidines throughout and blocked binding
to the RNA probe as effectively as VEGF-AS1. ODNs rich
in cytidines or cytidines/guanidines (C+,G C +) produced little
or no inhibition of binding. Next, we truncated VEGF-AS1
to better determine the components that were necessary for
optimal competition of this ODN. As shown in the lower
panel, the 30 end possessed sequences necessary for complete
inhibition of binding (VEGF-AS1b) versus no inhibition with
the 50 end (VEGF-AS1a). When the thymidine stretch was
truncated to 10 residues, there was some decrease in binding
inhibition (VEGF-AS1b.1). As the thymidines were further
truncated, there was progressive reduction in inhibition
Figure 3. TIARbindingtoIL-830-UTRiscompetedbythymidine-richODNs.(A)CompetitorODNswereaddedatthesametimeastheIL-830-UTRprobepriorto
UVcrosslinking.Theresultantbandwasquantitatedbyphosphorimagerandcomparedwiththebandintensitywhennocompetitorwasadded.Theresultsrepresent
anaverageofthreeexperiments.Arepresentativeblotisshownontheright.(B)UVcrosslinkingofHS578tbreastcancercellextracttoIL-830-UTRriboprobeinthe
presence of unlabeled ODNs (10-fold excess over probe) as indicated.
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(VEGF-AS1b.2). The potency of inhibition cannot be totally
explained by the number of consecutive thymidines since
VEGF-S2 has thymidine stretches interspersed with adenines,
with the longest stretch being 6 nt. To conﬁrm that this binding
inhibition was limited to the TIAR–RNP complex, we per-
formed UV crosslinking of HS578t nuclear extracts in the
presence of VEGF-AS1a and VEGF-AS1b at 10-fold excess
of the IL-8 RNA probe. There was complete obliteration of the
TIAR complex with VEGF-AS1b, similar to the full-length
VEGF-AS1 ODN (Figure 3B). No signiﬁcant changes were
observed with HuR, KSRP or other unidentiﬁed RNP com-
plexes, indicating the speciﬁcity of inhibition. As with the
UV crosslinking of recombinant TIAR, VEGF-AS1a, which
lacked any extended thymidine stretches, did not inhibit
TIAR–RNP complex formation.
We evaluated whether the DNA-binding capacity of TIAR
was limited to ssDNA. We utilized the negative control,
VEGF-AS2, and its compliment, VEGF-S2, which potently
inhibited IL-8 30-UTR RNA binding to TIAR. We pre-
hybridized the labeled VEGF-S2 ODN with varying amounts
of unlabeled complementary ODN (VEGF-AS2), and then UV
crosslinked the mixture to TIAR (Figure 4A). As expected,
VEGF-S2 bound to TIAR (upper panel). When the probe was
hybridized to VEGF-AS2, even at 2-fold excess, there was
near complete obliteration of binding. However, when a non-
complementary ODN was added (C+), there was continued
binding even at 20-fold excess (middle panel). No appreciable
binding was observed with radiolabeled VEGF-AS2, alone or
when hybridized to VEGF-S2 (lower panel). We conﬁrmed
these observations using EMSA (Figure 4B). The VEGF-S2
ODN produced a strong shifted complex, which was gradually
obliterated when the probe was pre-hybridized with increasing
amounts of unlabeled VEGF-AS2. The C+ ODN at 20-fold
excess did not affect the shifted band. Both assays indicated
that the TIAR binds only to ssDNA.
A DNA-binding locus is present outside of the
RNA-binding site
We next determined whether the DNA-binding capacity of
TIAR was solely related to the U-rich RNA-binding site.
To address this question, we performed a series of competition
assays utilizing IL-8 30-UTR and VEGF-AS1 probes
(Figure 5A). We analyzed binding to TIAR in the presence
of four different unlabeled competitors, VEGF-AS1, VEGF-
AS1b, rVEGF-AS1 and an IL-8 30-UTR in vitro transcript.
TIAR bound to IL-8 30-UTR, and the binding was competed
by all four competitors. Interestingly, the DNA competitors
blocked binding at lower concentrations than either the IL-8
30-UTR transcript or rVEGF-AS1, suggesting that the DNA
molecule had a higher afﬁnity for TIAR. On the other hand,
neither RNA competitor could compete with binding to
VEGF-AS1 even at 50-fold excess. This ﬁnding suggested
two possibilities. First, that there is an additional DNA-
binding site(s) outside of the RNA-binding site. A previous
report identiﬁed RRM2 as the locus for U-rich binding (4), but
did not demonstrate any RNA target for RRM1. The second
possibility is that the binding afﬁnity to DNA is signiﬁcantly
greater than to RNA. The latter possibility was tested by
increasing the amount of rVEGF-AS1 competitor to 200-fold.
At this concentration, there was only a modest diminution
of binding (data not shown), suggesting the presence of
an additional DNA-binding site(s) within TIAR, distinct
from the RNA-binding locus. As an alternative approach to
test this possibility, we pre-crosslinked TIAR with unlabeled
rVEGF-AS1 or VEGF-AS1b ODN, and then tested the protein
for binding to the DNA or RNA probe by EMSA (Figure 5B).
Lanes 1 and 2 show shifted complexes in the control reactions
with labeled DNA and RNA oligonucleotides using uncross-
linked TIAR. When TIAR is pre-crosslinked with unlabeled
VEGF-AS1, there is a loss of shifted complex with both the
DNA probe (lane 3) and the RNA probe (lane 4). On the other
hand, when the protein is pre-crosslinked with RNA, a shifted
complex is still produced with the DNA probe similar to the
control (compare lanes 1 and 5). The RNA probe, however,
fails to produce any substantial shift (lane 6). Thus, both the
Figure 4. TIAR binds only to ssDNA. (A) Labeled VEGF-S2 ODN probe was
pre-hybridized to its complementary ODN (VEGF-AS2) at varying concentra-
tions and then incubated with recombinant TIAR and UV crosslinked (upper
panel). A non-complementary ODN (C+) was used as a control hybridization
ODN (middle panel). The same experiment was repeated with labeled VEGF-
AS2 as a probe and VEGF-S2 as the hybridization ODN (lower panel). (B)
EMSA of the VEGF-S2 ODN probe after duplexing with the complementary
ODN (VEGF-AS2) or C+ at the concentrations (relative to probe) indicated.
4512 Nucleic Acids Research, 2005, Vol. 33, No. 14UV crosslinking and EMSA data strongly suggest the presence
of an additional DNA-binding site(s) outside of the RNA-
binding locus.
TIAR possesses two distinct loci for DNA-binding
activity
We next determined the binding loci within TIAR for DNA
ligands using deletion mutagenesis. We created a series of
truncated mutations spanning the TIAR protein (Figure 6).
Each mutant was made with a C-terminal His tag similar to
the wild-type protein. The protein product was veriﬁed by
western blotting using an anti-His tag antibody. To determine
binding afﬁnity, we used the UV-crosslinking method with
recombinant protein in excess of probe. As shown in
Figure 7 (upper panel), the full-length TIAR bound to both
DNA (VEGF-AS1) and RNA (rVEGF-AS1) oligonucleotides
with high afﬁnity, but not to a control ODN (VEGF-AS2). The
afﬁnity for DNA was  6-fold greater than RNA (Kdapp ¼
1.6 · 10
 9 M versus 9.4 · 10
 9 M). The afﬁnity for
rVEGF-AS1 was similar to the Kdapp reported elsewhere
(8.0 · 10
 9 M) for TIAR and U-rich sequences using a ﬁlter
binding assay (4). To deﬁne further the domains involved
with DNA binding, we evaluated a truncated protein lacking
the ﬁrst RRM (RRM2,3, middle panel). This mutant retained
both DNA and RNA-binding capacities although at a several
fold lower afﬁnity than the full-length protein (Kdapp ¼
3.0 · 10
 9 M for the DNA probe and 3.5 · 10
 8 M for
the RNA probe). However, when both RRM1 and RRM2
were deleted, no RNA or DNA binding was observed
(RRM 3, data not shown). These data are consistent with
previous observations that RRM2 was essential for binding
of U-rich RNA (4). We next tested a mutant expressing only
RRM1 (lower panel). This mutant bound to VEGF-AS1 but
not the RNA counterpart, rVEGF-AS1. The binding afﬁnity
(Kdapp ¼ 4.3 · 10
 8 M) was lower than full-length protein
or the RRM2,3 mutant, and no binding was observed with
VEGF-AS2. Thus, a second T-rich DNA-binding domain
resided in RRM1.
TIAR binding to DNA is displaced by active
transcription
One potential role for the dual binding capacity of TIAR
would be to shuttle between DNA and RNA molecules, poten-
tially even bridging them. One of the main loci where ssDNA
Figure 5. ADNA-binding locuscan beseparatedfromthe RNA-bindingsite.(A) UV-crosslinking reactionswithVEGF-AS1ODNorrIL-830-UTR(RNA)probes
and recombinant TIAR were performed in the presence of competitors as indicated. (B) TIAR was pre-crosslinked with rVEGF-AS1 (R) or VEGF-AS1b (D)
oligonucleotides (as indicated by UVX) and then assayed by EMSA using radiolabeled R or D probes.
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example, which is one of the deﬁned roles of TIAR and TIA-1
with respect to RNA binding, is known to occur concurrently
with transcription at the same locus (25,26). Effective shut-
tling to RNA would require overcoming the nearly 6-fold
greater afﬁnity of TIAR for DNA ligands. Since our com-
petition data indicated that TIAR binding to DNA could not
be displaced by excessive RNA concentrations, one possible
scenario would be displacement of DNA binding by active
transcription. To test this possibility in vitro, we synthesized
an ODN (Figure 8A) that contained a single-stranded TIAR
bindingsite(doubleasterisk)andaT7promotersite.Wechose
most of the VEGF-AS1b sequence for the TIARbinding locus.
The ODN was also designed such that when rCTP was not
added to the reaction, the transcript would stall prior to the
TIAR binding site (denoted by the single asterisk). We ﬁrst
tested whether this single-stranded template (duplexed at the
T7 promoter site) could direct transcription. A full-length
transcript was formed (Figure 8B, lane 1) with rCTP in
the transcription reaction. When rCTP was not added, a trun-
cated transcript was formed (lane 2). Thus, the partially
duplexed ODN was an adequate template for RNA transcrip-
tion. With the full-length transcript, we were able to demon-
strate binding to TIAR by UV crosslinking (Figure 8C, lane 1).
The shortened transcript, which is relatively U-rich, produced
a faint band suggestive of binding as well (lane 2). We next
radiolabeled the template strand of this partially duplexed
ODN and pre-incubated it with TIAR prior to transcription.
T7 RNA polymerase was then added tothe reaction forvarious
time points up to 45 min. The reaction was subjected to UV
crosslinking and then immunoprecipitated with the anti-TIAR
antibody(Figure 8D). We observed a progressive loss of TIAR
binding to the ODN over the 45 min incubation period. When
no polymerase was added, TIAR binding remained strong at
45 min (C1). When polymerase was added in the absence of
rCTP, TIAR also remained bound to the ODN similar to the
control (C2). The intensiﬁcation of crosslinked TIAR in the
controls compared with the time just prior to adding poly-
merase (0 min) is likely due to the increased time for labeled
ODN to bind TIAR. These results indicate that active tran-
scription through the TIAR binding site was necessary for
displacement of the protein from its DNA-binding site.
DISCUSSION
TIAR was ﬁrst identiﬁed as an RNA-binding protein with
three homologous RRMs in tandem and a glutamine-rich
C-terminal domain (3). The protein, which is closely related
to TIA-1, has a predilection for binding U-rich sequence, and
its role in alternative splicing and translational silencing has
been linked to binding U-rich regions near 50 splice sites or in
30-UTRs (4,5). The potent and selective disruption of TIAR
binding to IL-8 or VEGF-30-UTR riboprobes by VEGF-AS1
ODN suggested that the DNA and RNA ligands were com-
peting for the same binding locus (Figure 1). Previous analysis
of TIAR and TIA-1 revealed that RRM2 alone conferred spe-
ciﬁcity of binding to U-rich sequence (4). The overlap with
DNA binding was conﬁrmed by mutation analysis whereby
RRM2,3, but not RRM3 alone, bound to both RNA and DNA
ligands at afﬁnities approaching that of full-length protein
(Figure 7). Several observations from the competition studies,
however, supported the possibility that TIAR has an additional
DNA-binding locus. First, VEGF-AS1 ODN effectively com-
peted with U-rich RNA probes for TIAR binding, but neither
rVEGF-AS1 nor IL-8 30-UTR transcript could abrogate DNA
binding even at high concentrations (Figure 5). Second, when
TIAR was pre-crosslinkedto rVEGF-AS1, it could still readily
produce a shifted complex with VEGF-AS1 probe. Finally,
with mutational studies, it became clear that RRM1 could
independently bind T-rich DNA ligands (Figure 7). In an
earlier study of TIAR and TIA-1, no RNA target was identiﬁed
forRRM1evenusinglabeledtotalcellularRNA asaprobe (4).
Our construct, which used a different fusion tag, also did not
bind to U-rich RNA ligands. These combined ﬁndings suggest
that RRM1 only recognizes DNA ligands; however, it is pos-
sible that the RNA-binding capacity is preserved only in the
context of full-length protein. Binding properties (afﬁnity and
speciﬁcity) of RRMs can change substantially when analyzed
in isolation or in different combinations. For example, the four
RRMs of poly(A) binding protein, when expressed individu-
ally, do not bind poly(A) RNA efﬁciently or speciﬁcally (27).
Similarly, with hnRNPA1, the speciﬁcity in target RNA lig-
ands differed for the individual two RRMs of this protein
compared with full-length protein. Synergy that occurs
between RRMs to promote RNA binding may also explain
the lower afﬁnity of the RRM1 construct for T-rich ligands
(28–30). In the original binding studies of TIAR, the lack of
RNA binding by RRM1 was postulated to be related to an
atypical RNP1 motif in RRM1 (4). Usually the ﬁrst position of
Figure 6. Wild-type and truncated TIAR mutant constructs used in binding
analysis to DNA and RNA ligands. (A) Schematic representation of the TIAR
protein and the mutant constructs. (B) Western blot of the constructs using an
anti-His tag antibody.
4514 Nucleic Acids Research, 2005, Vol. 33, No. 14this motif is occupied by a basic amino acid residue, whereas
in RRM1 of TIAR there is a negatively charged amino acid
(aspartic acid). RNP motifs are the most highly conserved
elements in the RRM and, based on structural analysis, are
present in two adjacent b-sheets that provide a surface for
RNA binding through ring stacking (31–34). Positively
charged amino acid residues in position 1 may serve to
form salt bridges with the negatively charged phosphate back-
bone of the RNA and stabilize binding. This residue was
essential for U1A binding, for example, as substitution of
arginine with uncharged glutamine totally disrupted RNA
binding (35). However, the amino acid requirements are not
absolute, as substitutions of aspartic acid for hydrophobic
residues in RNP1 did not disrupt binding of HSH49, a
yeast splicing factor, to its RNA target (36). Thus, it is not
apparent from primary sequence or known structure as to why
RRM1 of TIAR would bind DNA rather than RNA. RRM1 is
also the locus of alternative splicing for TIAR, whereby a
‘long’ form is created with a 17 amino acid insertion between
RNP1 and 2 (3). In this study, we analyzed the ‘short’ form in
recombinant protein experiments and cannot comment on
what additional effects on speciﬁcity or afﬁnity of binding
this insertion would confer.
The dual capacity to bind RNA and DNA ligands is not
unique to TIAR, and occurs in a number of proteins with
RRMs and other types of RNA-binding domains (e.g. KH
and RGG) (37–39). However, the varying afﬁnity for RNA
versus DNA and double-stranded DNA (dsDNA) versus
ssDNA suggests that binding properties of a RRM are speciﬁc
rather than ‘generic’ for DNA. Even closely related hnRNPs,
such as AUF1 and hnRNP DOB, both of which have homo-
logous RRMs that bind AU-rich RNAs, have markedly dif-
ferent afﬁnities for DNA (40). With TIAR, the nearly 6-fold
higher afﬁnity for DNA over RNA, however, was surprising
since RRMs in general bind preferably to RNA (39). Several
notable exceptions include Stage-speciﬁc activator protein
(SSAP) from sea urchin and Gbp1p, a telomere-binding pro-
tein from Chlamydomonas reinhardtii (41–43). The former
binds with high afﬁnity to ssDNA derived from sequences
in the enhancer element of late histone H1 gene, but very
weakly to RNA counterparts. Gbp1, on the other hand, pos-
sesses two RRMs and binds strongly to G-strand telomeric
ssDNA when dimerized, but only weakly to the cognate RNA
sequence. Interestingly, while both proteins bind more avidly
to DNA, SSAP binds both dsDNA and ssDNA, whereas Gbp1
binds only to ssDNA. Here, we found that TIAR binds only to
Figure 7. Binding affinity analysis of TIAR and mutants. Proteins were in molar excess of probe (indicated in legend) and were UV crosslinked as described in
MaterialsandMethods.Boundprobewasquantitateddensitometricallybyphosphorimaging(shownintherightpanels).Affinitycurvesareshownontheleftandthe
Kdapp shown in the legend was extrapolated from the curve. The y-axis for DNA probes is on the left and on the right for RNA probes. The curves shown are
representative of a single experiment, but the analysis was repeated at least two times with similar results.
Nucleic Acids Research, 2005, Vol. 33, No. 14 4515ssDNA and that duplexing the ligand inhibits binding. This
ﬁnding is in contrast to the double-stranded binding properties
of the closely related T-cluster binding protein (TCBP) (44).
This protein was identiﬁed through screening of a phage
library with a concatenated double-stranded oligomer consist-
ing of 26 thymidines. It is 100% homologous with TIAR in
RRMs 2 and 3, but lacks a glutamine-rich C-terminus and a
complete RRM1. Our mutant RRM2,3 most closely resembles
this protein yet clearly binds ssDNA (Figure 7). While a
glutamine-richdomaincanaffect bindingactivitiesofattached
RRMs(28),itunlikelyplaysarolehereindeterminingdouble-
stranded versus single-stranded afﬁnity since the RRM1
mutant of TIAR bound to ssDNA.
The capacity of TIAR (and TIA-1) to bind ssDNA poten-
tially expands its functional role in nucleic acid metabolism.
The predominantly nuclear localization of TIAR (under nor-
mal conditions) places it in proximity to nuclear DNA (2,15).
Single-stranded conformations occur in chromatin undergoing
active transcription, possibly related to negative torsional
forces that create non-B-form DNA structure and local DNA
melting (45–47). Regions with high AT content, which TIAR
targets, are subject to greater bending and torsion, and thus
may be more apt to have local DNA melting (48,49). These
openings provide access for ssDNA-binding proteins as shown
with two KH-type RNA-binding proteins, HnRNP K and FBP.
These proteins bind to ssDNA conformations in far upstream
elements from the c-myc promoter and enhance transcription
(47,50–53). Reporter studies have also suggested that TCBP,
the dsDNA-binding homolog of TIAR, may function as a
transcriptional activator (44). Thus, TIAR may serve as a
modulator of transcription.
In light of TIAR’s role in alternative splicing, the dual
binding capacity of TIAR could allow shuttling between
RNA and DNA ligands. In our study, we found that TIAR
couldbindsimultaneouslytoRNAandDNAtargets(Figure5),
indicatingthatitmay possiblybridgethetwomolecules. There
is compelling evidence that pre-mRNA splicing (a function
of TIAR) is linked spatially and temporally to transcription,
whereby RNPparticleformationandintronremovalhave been
seen to occur on nascent transcripts (25,26,54,55).Thus, TIAR
may bind to T-rich ssDNA forms that occur within the tran-
scription template, either on the coding (e.g. VEGF-S2) or on
the non-coding (e.g. VEGF-AS1) strand in preparation for
shuttling to the pre-mRNA. To effectively shuttle, TIAR
would have to be displaced from its DNA-binding site to
permit binding to the pre-mRNA and participate in subsequent
RNA processing events. The substantially greater afﬁnity that
we observed with DNA binding could be offset by two pos-
sibilities: an increase in local concentration of U-rich tran-
scripts or the displacement of TIAR by active transcription.
For the former possibility, local competition between RNA
and ssDNA has been shown to occur with hnRNPA1/2
proteins that are involved in maintenance of telomeres
(56–58). These hnRNPs possess two RRMs that can bind
both the single-stranded RNA subunit of telomerase and
single-stranded telomeric repeat DNA. These proteins norm-
ally have a higher afﬁnity for telomeric RNA, but some inves-
tigators have proposed that this binding may be displaced in
favor of telomeric DNA in the 30 overhang as it is lengthened
by telomerase (59). In this study, DNA binding, however,
could not be displaced in vitro even with very high amounts
of RNA, most likely due to the second DNA-binding locus in
Figure8.TIARbindingtoDNAisdisplacedbytranscription.(A)PartiallyduplexedODNusedasatranscriptiontemplateforT7RNApolymerase.TheT7promoter
site is duplexed as shown. Single asterisk indicates the transcript synthesized if no rCTP is added, and double asterisk indicates the TIAR DNA-binding site.
(B)TranscriptionreactionusingthepartiallyduplexedODNinthepresence(lane1)orintheabsence(lane2)ofrCTP.Markers(labeledODNs)areshownontheleft.
(C) Results of UV crosslinking of TIAR with the labeledtranscripts shownin (B). (D) TIAR was prebound to the partially duplexed, radiolabeled (templatestrand)
ODN, and the complex was incubated with T7 RNA polymerase in the presence of rNTPs for various time intervals (0–45 min). The complex was then subjected
toUVcrosslinkingandimmunoprecipitatedwithananti-TIARantibody(shownintheblot).C1referstoacontrolreactioninwhichnoT7polymeraseisadded,and
C2 is a control reaction in which no rCTP is added.
4516 Nucleic Acids Research, 2005, Vol. 33, No. 14RRM1 outside of the RNA-binding locus. The second possi-
bility, supported by our in vitro transcription assay (Figure 8),
isthatTIARisdisplacedfromitsDNA-bindinglocusbyactive
transcription, thus freeing it to bind the nascent RNA tran-
script. The displacement may result from RNA–DNA duplex
formation during transcription or direct displacement by the
polymerase. In our in vitro model, TIAR was also able to bind
tothetranscriptthatencompassedtheDNA-bindingsite.Thus,
the nascent RNA may help sequester TIAR once it is displaced
from the DNA-binding site. In that scenario, the DNA-binding
capacity may serve the purpose of correctly positioning TIAR
for shuttling to the appropriate locus within the transcript
(e.g. to U-rich sequences in the pre-mRNA or the 30-UTR)
for subsequent RNA processing, transport or translational
regulation. For example, the recruitment of splicing factors
to the nascent RNA has typically been linked to protein–
protein interactions with RNA polymerase II [reviewed in
(25,26,60)]. The sequence-directed targeting may confer a
more speciﬁc and efﬁcient way of recruiting TIAR or other
splicing factors to the nascent RNA for processing. Clearly,
additional studies will be necessary to conﬁrm or exclude
whether this shuttling occurs in vivo.
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